Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Non-Current Assets (2016 - 2025)

Northwest Biotherapeutics' Non-Current Assets history spans 16 years, with the latest figure at $75.8 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $75.8 million for Q4 2025, up 234.3% from a year ago — trailing twelve months through Dec 2025 was $75.8 million (up 234.3% YoY), and the annual figure for FY2025 was $75.8 million, up 234.3%.
  • Non-Current Assets for Q4 2025 was $75.8 million at Northwest Biotherapeutics, up from $23.4 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $75.8 million in Q4 2025 to a low of $19.2 million in Q1 2021.
  • The 5-year median for Non-Current Assets is $23.0 million (2021), against an average of $25.0 million.
  • The sharpest move saw Non-Current Assets soared 245.17% in 2021, then fell 11.77% in 2022.
  • Year by year, Non-Current Assets stood at $22.9 million in 2021, then fell by 4.25% to $21.9 million in 2022, then rose by 8.41% to $23.7 million in 2023, then dropped by 4.52% to $22.7 million in 2024, then surged by 234.3% to $75.8 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $75.8 million, $23.4 million, and $23.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.